Bernard Bizzini

Pathogenic disorders involved in immunosuppression and T cell depletion characterizing AIDS.

A. Burny, J. Zagury, H. Le Coq, 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases.

A. Burny, R. Gallo, G. Lewis, 2003, Cytokine & growth factor reviews.

Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.

W. Blattner, A. Burny, J. Zagury, 1998, Journal of human virology.

Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).

Z. Bentwich, A. Burny, E. Santagostino, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS.

A. Gringeri, A. Lachgar, B. Bizzini, 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC).

J. Zagury, G. Jaureguiberry, J. Rappaport, 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Tat toxoid as a component of a preventive vaccine in seronegative subjects.

A. Burny, E. Santagostino, J. Zagury, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

C-C chemokines, pivotal in protection against HIV type 1 infection.

S. O’Brien, A. Burny, E. Santagostino, 1998, Proceedings of the National Academy of Sciences of the United States of America.